Interstitial Lung Disease Trial, Recruiting (NCT06527612)

Interstitial Lung Disease Trial, Recruiting NCT06527612 Sponsor: Istanbul Medipol University Hospital Condition: Interstitial Lung Disease

Printed from Voxsanity (voxsanity.com.au) — NCT06527612 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Interstitial Lung Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People aged between 18 and 75 years old.
People who have been diagnosed with a scarring lung disease called fibrosing interstitial lung disease, based on recognised medical guidelines.
People who experience breathlessness during physical activity or exercise.
People whose condition has been stable for at least 4 weeks, with no active infection or worsening of their condition during that time.
People who are comfortable and able to use a smartphone.

Who may not be able to join:

People with serious other health conditions, unstable heart (coronary artery) disease, connective tissue or autoimmune diseases affecting the body, or those who need high levels of supplemental oxygen (more than 3–4 litres per minute).
People who have a history of fainting during exercise, or who have any condition that prevents them from safely taking part in exercise training, such as severe bone, joint, or nerve problems, or an unstable heart condition.
People who have taken part in a formal lung rehabilitation program at any point in the past 12 months.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 26 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06527612

Sponsor: Istanbul Medipol University Hospital

Phase: Not Applicable

Status: Recruiting

Condition: Interstitial Lung Disease

More information: https://clinicaltrials.gov/study/NCT06527612

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People aged between 18 and 75 years old.
People who have been diagnosed with a scarring lung disease called fibrosing interstitial lung disease, based on recognised medical guidelines.
People who experience breathlessness during physical activity or exercise.
People whose condition has been stable for at least 4 weeks, with no active infection or worsening of their condition during that time.
People who are comfortable and able to use a smartphone.

Who may not be able to join:

People with serious other health conditions, unstable heart (coronary artery) disease, connective tissue or autoimmune diseases affecting the body, or those who need high levels of supplemental oxygen (more than 3–4 litres per minute).
People who have a history of fainting during exercise, or who have any condition that prevents them from safely taking part in exercise training, such as severe bone, joint, or nerve problems, or an unstable heart condition.
People who have taken part in a formal lung rehabilitation program at any point in the past 12 months.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 26 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Istanbul Medipol University Hospital

Registry

ClinicalTrials.gov

Start date

29 July 2024

Est. completion

1 August 2026

Where this trial is recruiting

Turkey (Türkiye)

Primary endpoints

Saint George Quality of life questionnaire; Forced vital capacity; Diffusing Capacity of the Lungs for Carbon Monoxide; Peripheral oxygen saturation

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov